Proposal No. 2 7 - 2 0 2

Proposal for Task Force Consideration at the ISSC 2027 Biennial Meeting *(Tab to go to next field)*	1. a. ☐ Growing Area b. ☒ Harvesting/Handling/Distribution c. ☐ Administrative
2. Submitter	US Food & Drug Administration (FDA)
3. Affiliation	US Food & Drug Administration (FDA)
4. Address Line 1	5001 Campus Drive
5. Address Line 2	
6. City, State, Zip	College Park, MD 20740
7. Phone	301-436-2601
8. Email	Melissa.Abbott@fda.hhs.gov
9. Proposal Subject	Federal No Discharge Zone
10. Specific NSSP Guide Reference	NSSP MO Section I Purposes & Definitions
11. Text of Proposal/ Requested Action	**(115) Shellfish** means all species of: a) Bivalve mollusks ~~including all species of~~ (~~e.g.,~~ e.g., oysters, clams, mussels, cockles, and scallops~~)~~ whether: i. Shucked or in the shell; ii. Raw, including post-harvest processed; iii. Frozen or unfrozen; iv. Whole or in part~~;~~ ~~and~~ except when the final product form is the adductor muscle only, attached or unattached to the shell. ~~Scallops in any form, except when the final product form is the adductor muscle only, attached or unattached to the shell.~~
12. Public Health Significance	Scallops, when their final form is the adductor muscle, are not currently covered by the NSSP because adductor muscles do not contain the same high risk as whole bivalve mollusks. Adductor muscles from other species represent a similar low risk and should be covered under 21 CFR 123 *Seafood HACCP*. There has been an increase in imported adductor muscles from other bivalve shellfish species and the FDA Division of Import Operations routinely requests evaluation of the imported product to determine if it is covered by the NSSP or the Code of Federal Regulations.
13. Cost Information	No cost.
14. Changes Needed to Guidance (if proposed change is adopted)	TBD